Surotomycin

DB12076InvestigationalSmall molecule

Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for... Surotomycin has a fourfold greater in vitro potency than vancomycin against C.

Formula / weight: C₇₇H₁₀₁N₁₇O₂₆ · 1680.748 g/mol (avg)
Code names: CB-183,315

Resolves to

Compound

UNIION0N776N05CAS1233389-51-9

Structure

InChIKeyDYNMYYRPPFVAKR-CWXHRMTKSA-NSMILES

CCCCCC1=CC=C(C=C1)C(\C)=C\C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O

What you can answer from here — as of May 14, 2021

3Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Surotomycin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account